Journal of Clinical Oncology
Articles in this Issue
Impact of liver function on survival outcomes in patients (pts) treated with first-line atezolizumab-bevacizumab (Atezo-Bev) for unresectable hepatocellular carcinoma (uHCC): Asia-Pacific multicenter retrospective analysis.
509 Background: Atezo-Bev is the established first-line therapy for uHCC, but pivotal trials included only pts with preser...
Phase II study of durvalumab plus olaparib in patients with metastatic pancreatic cancer and DNA damage repair gene alterations.
724 Background: Metastatic pancreatic cancer (mPC) with DNA damage repair (DDR) gene alterations, such as...
SOX (tegafur plus oxaliplatin) plus anti-PD-1 antibody with or without CAR-like T cell immunotherapy in the treatment of patients with previously untreated metastatic gastric cancer/gastroesophageal junction adenocarcinoma: A multicenter, open-label, randomized, controlled, phase II trial.
291 Background: Although PD-1 blockade plus chemotherapy has achieved response rate for advanced gastric/ gastroesophageal...
Healthful Plant-Based Diet Index (hPDI) and risk of upper gastrointestinal cancer: A meta-analysis.
331 Background: The relationship between plant-based dietary patterns and upper gastrointestinal (GI) cancers remains uncl...
Neoadjuvant chemotherapy and serplulimab in MSS/pMMR locally advanced rectal cancer (FIRM): A phase II trial.
119 Background: PD-1 inhibitor shows poor efficacy in MSS locally advanced rectal cancer (LARC). Radiotherapy activates tu...
Clinical performance of liquid RNA (L-RNA) biopsy in a gastrointestinal cancer segment.
27 Background: Exosomal RNAs mediate cellular communication, reflect dynamic physiological and pathological changes. Unlik...
Advancing multidisciplinary management of HCC with cirrhosis in community-based settings.
532 Background: Liver cancer mortality remains high in the US, with a 5-year survival rate of 22%. Most patients with hepa...
Prospective evaluation of zinc, clobetasol, and combination prophylaxis for regorafenib-induced hand-foot skin reaction in colorectal cancer: A subgroup analysis of the ZINCLO-HAND study.
115 Background: Regorafenib is an effective oral multikinase inhibitor approved for treatment-refractory metastatic colore...
Efficacy, disease stabilization, and toxicity outcomes of immune checkpoint inhibitors in gastroenteropancreatic neuroendocrine tumors: A meta-analysis.
638 Background: The role of immune checkpoint inhibitors (ICIs) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs)...
Molecular residual disease detection using whole-genome sequencing-based ctDNA assay for resectable colorectal cancer in the MONSTAR-SCREEN-3 project.
187 Background: Circulating tumor DNA (ctDNA) has been established as a strong predictive biomarker for post-surgical mole...
Clinical factors associated with advanced colorectal neoplasia in average-risk, asymptomatic individuals.
89 Background: Colorectal cancer (CRC) is a leading cause of cancer-related mortality in the U.S. Advanced precancerous le...
Sorbitol-supplemented diet combined with neoadjuvant chemoimmunotherapy in locally advanced gastric cancer: Preliminary results from a randomized controlled trial.
361 Background: Neoadjuvant chemoimmunotherapy is revolutionizing the treatment landscape for solid tumors. However, a sub...
Which patients with colorectal cancer develop brain metastases? A multicenter analysis of clinical and molecular predictors.
218 Background: Brain metastases from colorectal cancer (CRC) are rare but clinically significant events with limited data...
METEORITE: A phase II study of Y-90, capecitabine, and atezolizumab in oligometastatic CRC (BrUOG430).
TPS276 Background: Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. Patients with...
Prognostic role of PIK3CA and co-alterations in advanced biliary tract cancer: A multicenter retrospective analysis.
599 Background: Biliary tract cancers (BTC) remain aggressive malignancies with limited treatment options. Alterations in...
Real-world outcomes of combination immunotherapy in patients with Child–Pugh class B hepatocellular carcinoma.
556 Background: Systemic therapy for hepatocellular carcinoma (HCC) is primarily recommended for patients with preserved l...
Shared genetic susceptibility between autoimmune diseases and pancreatic ductal adenocarcinoma: A pathway-level analysis.
689 Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor prognosis and limited opti...
Bxq-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN—A phase 1b/2 trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic colorectal carcinoma.
105 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a significant side effect associated with many cancer...
Real-world analysis on the impact of GLP-1 receptor agonists on survival and metastatic risk in colorectal cancer.
62 Background: GLP-1 receptor agonists (GLP-1RAs), commonly prescribed for type 2 diabetes (T2DM) and obesity, have demons...
Real-world effectiveness and safety of apixaban versus rivaroxaban in pancreatic cancer–associated VTE.
739 Background: Pancreatic cancer is highly associated with venous thromboembolism (VTE), requiring long-term anticoagulat...
Helicobacter pylori and risk of esophageal cancer: A meta-analysis.
458 Background: Helicobacter pylori (Hp) is a recognized gastric carcinogen, but its role in esophageal cancer remains unc...
Mutational analysis and identification of potential biomarkers in patients with metastatic pancreatic cancer treated with the combination of the GSK-3 inhibitor elraglusib and gemcitabine/nab-paclitaxel in the 1801 Part 3B phase 2 study.
761 Background: Glycogen Synthase Kinase-3β (GSK-3β) is a known therapeutic target in cancer including pancreatic adenocar...
Utilization of immunotherapy as a neoadjuvant treatment in liver transplant recipients with hepatobiliary carcinoma.
570 Background: Hepatobiliary Carcinoma (HBC) ranks as the sixth most prevalent cancer worldwide. This study reports our i...
Total gastrectomy (TG) versus distal gastrectomy (DG) for distal diffuse gastric cancer (GC).
305 Background: Diffuse gastric cancer (GC) in advanced stages has a poor prognosis. There is no clear consensus regarding...
Redefining the use of a first-line FOLFIRINOX-like regimen in older patients with metastatic pancreatic cancer: Updated analysis.
700 Background: Prospective elderly-specific data for treating pancreatic cancer are scarce. First-line treatment with tri...